Alzheimer's disease: New prospects in therapy and applied experimental models;Choroba Alzheimera-nowe mozliwos̈ci terapeutyczne oraz stosowane modele eksperymentalne

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 372-392

  Kubis, Adriana M ^a   Janusz, Maria ^b  

^a UNIVERSITY OF WROC AW   (Poland)

^b Zak ad Immunochemii Instytut Immunologii i Terapii Dos wiadczalnej PAN Im Ludwika   (Poland)

Author keywords

Alzheimer disease; Ca2+ ions; Cytokines; Experimental models; Oxidative stress; Tau protein; Therapeutic prospects; amyloid

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYTOKINE; REACTIVE OXYGEN METABOLITE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; APOPTOSIS; DISEASE MODEL; GENETICS; HEALTH CARE FACILITY; HUMAN; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; NEURONS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TAU PROTEINS; TISSUE BANKS;

EID: 76749126036     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Aarli J.A.: Role of cytokines in neurological disorders. Curr. Med. Chem., 2003; 10: 1931-1937
2. Adessi C., Frossard M.J., Boissard C., Fraga S., Bieler S., Ruckle T., Vilbois F., Robinson S.M., Mutter M., Banks W.A., Soto C.: Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem., 2003; 278: 13905-13911
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T.: Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000; 21: 383-421
4. Alkam T., Nitta A., Mizoguchi H., Itoh A., Nabeshima T.: A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Ab(25-35). Behav. Brain Res., 2007; 180: 139-145
5. Allan S.M., Rothwell N.J.: Cytokines and acute neurodegeneration. Nat. Rev. Neurosci., 2001; 2: 734-744
6. Ancelin M.L., Christen Y., Ritchie K.: Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement. Geriatr. Cogn. Disord., 2007; 24: 1-19
7. Arbel M., Yacoby I., Solomon B.: Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies. Proc. Natl. Acad. Sci. USA, 2005; 102: 7718-7723
8. Arosio B., Trabattoni D., Galimberti L., Bucciarelli P., Fasano F., Calabresi C., Cazzullo C.L., Vergani C., Annoni G., Clerici M.: Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol. Aging, 2004; 25: 1009-1015
9. Aslan M., Ozben T.: Reactive oxygen and nitrogen species in Alzheimer's disease. Curr. Alzheimer Res., 2004; 1: 111-119
10. Babas T., Munoz D., Mankowski J.L., Tarwater P.M., Clements J.E., Zink M.C.: Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain. J. Virol., 2003; 77: 208-216
11. Bacsi A., Stanton G.J., Hughes T.K., Kruzel M., Boldogh I.: Colostrinindriven neurite outgrowth requires p53 activation in PC12 cells. Cell. Mol. Neurobiol., 2005; 25: 1123-1139
12. Beckman M.: Untangling Alzheimer's by paring plaques bolsters amyloid theory. Science, 2004; 305: 762
13. Beloosesky Y., Salman H., Bergman M., Bessler H., Djaldetti M.: Cytokine levels and phagocytic activity in patients with Alzheimer's disease. Gerontology, 2002; 48: 128-132
14. Benveniste E.N.: Inflammatory cytokines within the central nervous system: sources, function and mechanism of action. Am. J. Physiol. Cell. Physiol., 1992; 263: C1.C16
15. Bilikiewicz A., Gaus W.: Colostrinin (a naturally occurring, prolinerich, polypeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimers Dis., 2004; 6: 17-26
16. Birks J.: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., 2006; 1: CD005593
17. Birnie G.D.: The HL60 cell line: A model system for studying human myeloid cell differentiation. Br. J. Cancer Suppl., 1988; 9: 41-45
18. Blasko I., Apochal A., Boeck G., Hartmann T., Grubeck-Loebenstein B., Ransmayr G.: Ibuprofen decreases cytokine-induced amyloid b production in neuronal cells. Neurobiol. Dis., 2001; 8: 1094-1101
19. Blasko I., Grubeck-Loebenstein B.: Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging, 2003; 20: 101-113
20. Bonotis K., Krikki E., Holeva V., Aggouridaki C., Costa V., Baloyannis S.: Systemic immune aberrations in Alzheimer's disease patients. J. Neuroimmunol., 2008; 193:183-187
21. Braddock M.: Safely slowing down the decline in Alzheimer's disease: gene therapy shows potential. Expert Opin. Investig. Drugs, 2005; 14: 913-915
22. Brera B., Serrano A., de Ceballos M.L.: β-amyloid peptides are cytotoxic to astrocytes in culture: A role for oxidative stress. Neurobiol. Dis., 2000; 7: 395-405
23. Brzyska M., Elbaum D.: Dysregulation of calcium in Alzheimer's disease. Acta Neurobiol. Exp., 2003; 63: 171-183
24. Bucki R., Gorski J.: Wspo Czesne Pogldy Dotyczce Funkcji i Regulacji Stenia Ca2+ W J.drach Komorkowych. Post. Hig. Med. Do.w., 2001; 55: 157-175
25. Bullock R.: Galantamine: use in Alzheimer's disease and related disorders. Expert Rev. Neurother., 2004; 4: 153-163
26. Calabrese V., Bates T.E., Stella A.M.: NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: The role of oxidant/antioxidant balance. Neurochem. Res., 2000; 25: 1315-1341
27. Caselli R.J., Beach T.G., Yaari R., Reiman E.M.: Alzheimer's disease a century later. J. Clin. Psychiatry, 2006; 67: 1784-1800
28. Chen C.Y., Jang J.H., Park M.H., Hwang S.J., Surh Y.J., Park O.J.: Attenuation of Ab-induced apoptosis of plant extract (Saengshik) mediated by the inhibition of mitochondrial dysfunction and antioxidative effect. Ann. NY Acad. Sci., 2007; 1095: 399-411
29. Cho H.S., Hyman B.T., Greenberg S.M., Rebeck G.W.: Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Ab aggregation. J. Neuropathol. Exp. Neurol., 2001; 60: 342-349
30. Chong Y.H., Shin Y.J., Suh Y.H.: Cyclic AMP inhibition of tumor necrosis factor a production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol. Pharmacol., 2003; 63: 690-698
31. Christensen D.D.: Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr., 2007; 12: 113-123
32. Chu L.W., Yik P.Y., Mok W., Chung C.P.: A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Int. J. Clin. Pract., 2007; 61: 403-410
33. Collins S.J.: The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood, 1987; 70: 1233-1244
34. Combs C.K., Karlo J.C., Kao S.C., Landreth G.E.: β-amyloid stimulation of microglia and monocytes results in TNFa-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001; 21: 1179-1188
35. Corzo L., Zas R., Rodríguez S., Fernández-Novoa L., Cacabelos R.: Decreased levels of serum nitric oxide in different forms of dementia. Neurosci. Lett., 2007; 420: 263-267
36. Craft J.M., Watterson D.M., Van Eldik L.J.: Human amyloid β-induced neuroinflammation is an early event in neurodegeneration. Glia, 2006; 53: 484-490
37. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L.: A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem., 2007; 282: 11590-11601
38. Dobryszycka W., Gsiorowski K., Leszek J.: Metaboliczne podstawy choroby Alzheimera. W: Demencje wieku podeszego. Patomechanizm i strategie leczenia. Wyd. Continuo, 2004; 9-45
39. Dobryszycka W., Leszek J., Rymaszewska J.: Blaszki starcze. W: Choroba Alzheimera. Patogeneza, diagnostyka, leczenie. Wyd. Continuo, 2002; 13-25
40. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J.: The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural. Transm., 2006; 113: 1685-1695
41. Eperon S., Jungi T.W.: The use of human monocytoid lines as indicators of endotoxin. J. Immunol. Methods, 1996; 194: 121-129
42. Farlow M.R., Cummings J.L.: Effective pharmacologic management of Alzheimer's disease. Am. J. Med., 2007; 120: 388-397
43. Feigin A., Eidelberg D.: Gene transfer therapy for neurodegenerative disorders. Mov. Disord., 2007; 22: 1223-1228
44. Feldman H.H., Ferris S., Winblad B., Sfikas N., Mancione L., He Y., Tekin S., Burns A., Cummings J., del Ser T., Inzitari D., Orgogozo J.M., Sauer H., Scheltens P., Scarpini E., Herrmann N., Farlow M., Potkin S., Charles H.C., Fox N.C., Lane R.: Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurol., 2007; 6: 501-512
45. Fiala M., Cribbs D.H., Rosenthal M., Bernard G.: Phagocytosis of amyloid-b and inflammation: two faces of innate immunity in Alzheimer's disease. J. Alzheimers Dis., 2007; 11: 457-463
46. Filipcik P., Cente M., Ferencik M., Hulin I., Novak M.: The role of oxidative stress in the pathogenesis of Alzheimer's disease. Bratisl. Lek. Listy, 2006; 107: 384-394
47. Flirski M., Sobow T.: Biochemical markers and risk factors of Alzheimer's disease. Curr. Alzheimer Res., 2005; 2: 47-64
48. Fraser P.E., Yang D.S., Yu G., Lévesque L., Nishimura M., Arawaka S., Serpell L.C., Rogaeva E., St. George-Hyslop P.: Presenilin structure, function and role in Alzheimer disease. Biochim. Biophys. Acta, 2000; 1502: 1-15
49. Gadient R.A., Otten U.H.: Interleukin-6 (IL-6)-A molecule with both beneficial and destructive potentials. Prog. Neurobiol., 1997; 52: 379-390
50. Gambi F., Reale M., Iarlori C., Salone A., Toma L., Paladini C., De Luca G., Feliciani C., Salvatore M., Salerno R.M., Theoharides T.C., Conti P., Exton M., Gambi D.: Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1b levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol., 2004; 24: 314-321
51. Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., Lu M., Fu Y., Garcia-Sierra F., LaPointe N., Miller R., Berry R.W., Binder L.I., Cryns V.L.: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer,s disease. Proc. Natl. Acad. Sci. USA, 2003; 100: 10032-10037
52. Gandy S., Petanceska S.: Regulation of Alzheimer β-amyloid precursor trafficking and metabolism. Biochim. Biophys. Acta, 2000; 1502: 44-52
53. Gebicke-Haerter P.J.: Microglia in neurodegeneration: molecular aspects. Microsc. Res. Tech., 2001; 54: 47-58
54. Geldmacher D.S.: Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert. Rev. Neurother., 2004; 4: 5-16
55. Gelinas D.S., DaSilva K., Fenili D., St. George-Hyslop P., McLaurin J.: Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004; 101(Suppl. 2): 14657-14662
56. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M.: Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005; 64: 1553-1562
57. Glabe C.: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neurosci., 2001; 17: 137-145
58. Golde T.E.: Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest., 2003; 111: 11-18
59. Golde T.E.: The Ab hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol., 2005; 15: 84-87
60. Götz J.: Tau and transgenic animal models. Brain Res. Brain Res. Rev., 2001; 35: 266-286
61. Götz J., Deters N., Doldissen A., Bokhari L., Ke Y., Wiesner A., Schonrock N., Ittner L.M.: A decade of tau transgenic animal models and beyond. Brain Pathol., 2007; 17: 91-103
62. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L. III, Araoz C.: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1989; 86: 7611-7615
63. Griffin W.S., Liu L., Li Y., Mrak R.E., Barger S.W.: Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflammation, 2006; 3: 5
64. Grzanna R., Phan P., Polotsky A., Lindmark L., Frondoza C.G.: Ginger extract inhibits β-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. J. Altern. Complement. Med., 2004; 10: 1009-1013
65. Guo J.P., Arai T., Miklossy J., McGeer P.L.: Ab and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006; 103: 1953-1958
66. Hardy J.: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci., 1997; 20: 154-159
67. Hartmann R., Meisel H.: Food-derived peptides with biological activity: from research to food applications. Curr. Opin. Biotechnol., 2007; 18: 163-169
68. Heneka M.T., O'Banion M.K.: Inflammatory processes in Alzheimer's disease. J. Neuroimmunol., 2007; 184: 69-91
69. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A, Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M.: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003; 38: 547-554
70. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W.: Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. USA, 2001; 98: 8838-8843
71. Hyman B.T., Growdon J.H.: Can the immune system fight Alzheimer disease? Nat. Med., 2006; 12: 755-756
72. Ichikawa M., Sugita M., Takahashi M., Satomi M., Takeshita T., Araki T., Takahashi H.: Breast milk macrophages spontaneously produce granulocyte-macrophage colony-stimulating factor and differentiate into dendritic cells in the presence of exogenous interleukin-4 alone. Immunology, 2003; 108: 189-195
73. Ischiropoulos H., Beckman J.S.: Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest., 2003; 111: 163-169
74. Kelso A.: Cytokines: principles and prospects. Immunol. Cell Biol., 1998; 76: 300-317
75. Kim D.S., Kim J.Y., Han Y.S.: Alzheimer's disease drug discovery from herbs: neuroprotectivity from beta-amyloid (1-42) insult. J. Altern. Complement. Med., 2007; 13: 333-340
76. Kitamura T., Sugimori K., Sudo S., Kobayashi K.: Relationship between microtubule-binding repeats and morphology of neurofibrillary tangle in Alzheimer's disease. Acta Neurol. Scand., 2005; 112: 327-334
77. Kivipelto M., Solomon A., Winblad B.: Alzheimer's Disease: back to the future. Acta Neurol. Scand., 2006; 114: 119-120
78. Kolarski W.: Podstawowe typy komórek i tkanek. W: Strukturalne podstawy biologii komórki. Wyd. PWN, 2003; 55-60
79. Kowalska A.: Hipoteza kaskady β-amyloidu-sekwencja wydarzeń prowadzących do neurodegeneracji w chorobie Alzheimera. Neurol. Neurochir. Pol., 2004; 38: 405-411
80. Lee H.G., Castellani R.J., Zhu X., Perry G., Smith M.A.: Amyloid-b in Alzeimer's disease; the horse or the cart? Pathogenic or protective? Int J. Exp. Pathol., 2005; 86: 133-138
81. Lemere C.A.: A beneficial role for IL-1 b in Alzheimer disease? J. Clin. Invest., 2007, 117:1483-1485
82. Leong S.K., Ruan R.S., Zhang Z.: A critical assessment of the neurodestructive and neuroprotective effects of nitric oxide. Ann. NY Acad. Sci., 2002; 962: 161-181
83. Leszek J., Inglot A.D., Janusz M., Byczkiewicz F., Kiejna A., Georgiades J.A., Lisowski J.: Colostrinin proline-rich polypeptide complex from ovine colostrum-A long-term study of its efficacy in Alzheimer's disease. Med. Sci. Monit., 2002; 8: PI93-PI96
84. Leszek J., Inglot A.D., Janusz M., Lisowski J., Krukowska K., Georgiades J.A.: Colostrinin→: A proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch. Immunol. Ther. Exp., 1999; 47: 377-385
85. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M.: Increased plasma levels of interleukin-1, interleukin-6 and 1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol., 2000; 103: 97-102
86. Lopez J.C.: Neurodegeneration⋯ β-secretase unmasked. Nat. Rev. Neurosci., 2001; 2: 222-223
87. Lynch T., Cherny R.A., Bush A.I.: Oxidative processes in Alzheimer's disease: The role of Ab-metal interactions. Exp. Gerontol., 2000; 35: 445-451
88. Maccioni R.B., Munoz J.P., Barbeito L.: The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res., 2001; 32: 367-381
89. Makrides V., Massie M.R., Feinstein S.C., Lew J.: Evidence for two distinct binding sites for tau on microtubules. Proc. Natl. Acad. Sci. USA, 2004; 101: 6746-6751
90. Markesbery W.R., Carney J.M.: Oxidative alterations in Alzheimer's disease. Brain Pathol., 1999; 9: 133-146
91. Marlatt M.W., Webber K.M., Moreira P.I., Lee H.G., Casadesus G., Honda K., Zhu X., Perry G., Smith M.A.: Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr. Med. Chem., 2005; 12: 1137-1147
92. Marx J.: Alzheimer's disease. A new take on tau. Science, 2007; 316: 1416-1417
93. Masters C.L., Cappai R., Barnham K.J., Villemagne V.L.: Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J. Neurochem., 2006; 97: 1700-1725
94. Mattson M.P.: Pathways towards and away from Alzheimer's disease. Nature, 2004; 430: 631-639
95. McGowan E., Eriksen J., Hutton M.: A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet., 2006; 22: 281-289
96. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci., 2007; 27: 5394-5404
97. Monsonego A., Weiner H.L.: Immunotherapeutic approaches to Alzheimer's disease. Science, 2003; 302: 834-838
98. Mooren F.C., Kinne R.K.: Cellular calcium in health and disease. Biochim. Biophys. Acta, 1998; 1406: 127-151
99. Morinaga A., Hirohata M., Ono K., Yamada M.: Estrogen has anti-amyloidogenic effects on Alzheimer's β-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun., 2007; 359: 697-702
100. Morris J.C.: Is Alzheimer's disease inevitable with age?: Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer's disease. J. Clin. Invest., 1999; 104: 1171-1173
101. Mrak R.E., Griffin W.S.: Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging, 2001; 22: 903-908
102. Munoz L., Ranaivo H.R., Roy S.M., Hu W., Craft J.M., McNamara L.K., Chico L.W., Van Eldik L.J., Watterson D.M.: A novel p38a MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflammation, 2007; 4: 21
103. Murphy R.M.: Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng., 2002; 4: 155-174
104. Nagele R.G., D'Andrea M.R., Lee H., Venkataraman V., Wang H.Y.: Astrocytes accumulate Ab42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res., 2003; 971: 197-209
105. Nakamura Y.: Regulating factors for microglial activation. Biol. Pharm. Bull., 2002; 25: 945-953
106. Napryeyenko O., Borzenko I.: Gingko biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung, 2007; 57: 4-11
107. New York Brain Bank at Columbia University. http://nybb.hs.columbia. edu (19-06.2008)
108. Octave J.N., Essalmani R., Tasiaux B., Menager J., Czech C., Mercken L.: The role of presenilin-1 in the g-secretase cleavage of the amyloid precursor protein of Alzheimer's disease. J. Biol. Chem., 2000; 275: 1525-1528
109. Oliveira A.A.Jr., Hodges H.M.: Alzheimer's disease and neural transplantation as prospective cell therapy. Curr. Alzheimer Res., 2005; 2: 79-95
110. Orellana D.I., Quintanilla R.A., Maccioni R.B.: Neuroprotective effect of TNF a against the β-amyloid neurotoxicity mediated by CDK5 kinase. Biochim. Biophys. Acta, 2007; 1773: 254-263
111. Ostrowski M., Grzanka A., Izdebska M.: Rola aktyny w chorobie Alzheimera. Post. Hig. Med. Dos̈w., 2005; 59: 224-228
112. Ott B.R., Blake L.M., Kagan E., Resnick M.: Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J. Neurol., 2007; 254: 351-358
113. Panda D., Samuel J.C., Massie M., Feinstein S.C., Wilson L.: Differential regulation of microtubule dynamics by three-and fourrepeat tau: implications for the onset of neurodegenerative disease. Proc. Natl. Acad. Sci. USA, 2003; 100: 9548-9553
114. Pappolla M.A., Smith M.A., Bryant-Thomas T., Bazan N., Petanceska S., Perry G., Thal L.J., Sano M., Refolo L.M.: Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic. Biol. Med., 2002; 33: 173-181
115. Pearson H.A., Peers C.: Physiological roles for amyloid b peptides. J. Physiol., 2006; 575: 5-10
116. Pinnix I., Musunuru U., Tun H., Sridharan A., Golde T., Eckman C., Ziani-Cherif C., Ontstead L., Sambamurti K.: A novel gamma secretase assay based on detection of the putative C-terminal fragmentgamma of APP. J. Biol. Chem., 2001; 276: 481-487
117. Potyk D.: Treatments for Alzheimer disease. South. Med. J., 2005; 98: 628-635
118. Prada C.M., Garcia-Alloza M., Betensky R.A., Zhang-Nunes S.X., Greenberg S.M., Bacskai B.J., Frosch M.P.: Antibody-mediated clearance of amyloid-b peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J. Neurosci., 2007; 27:1973-1980
119. Primate Brain Bank. http://www-vf.bio.uu.nl/-webmanager/PBB/PBB-Start.html (19-06.2008)
120. Quan N., Herkenham M.: Connecting cytokines and brain: A review of current issues. Histol. Histopathol., 2002; 17: 273-288
121. Rajanikant G.K., Zemke D., Kassab M., Majid A.: The therapeutic potential of statins in neurological disorders. Curr. Med. Chem., 2007; 14: 103-112
122. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T.: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med., 2007; 13: 1359-1362
123. Remarque E.J., Bollen E.L., Waverling-Rijnsburger A.W., Laterveer J.C., Blauw G.J., Westendorp R.G.: Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol., 2001; 36: 171-176
124. Riekse R.G., Li G., Petrie E.C., Leverenz J.B., Vavrek D., Vuletic S., Albers J.J., Montine T.J., Lee V.M., Lee M., Seubert P., Galasko D., Schellenberg G.D., Hazzard W.R., Peskind E.R.: Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J. Alzheimers Dis., 2006; 10: 399-406
125. Robak T. Biologia i farmakologia cytokin. Wydawnictwo PWN, Warszawa, 1995; 13-73, 122.133, 156.161, 255.262.
126. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L.: Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science, 2007; 316: 750-754
127. Rogers J., Strohmeyer R., Kovelowski C.J., Li R.: Microglia and inflammatory mechanisms in the clearance of amyloid b peptide. Glia, 2002; 40: 260-269
128. Sala G., Galimberti G., Canevari C., Raggi M.E., Isella V., Facheris M., Appollonio I., Ferrarese C.: Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging, 2003; 24: 909-914
129. Saura J.: Microglial cells in astroglial cultures: A cautionary note. J. Neuroinflammation, 2007; 4: 26
130. Saurwein-Teissl M., Blasko I., Zisterer K., Neuman B., Lang B., Grubeck-Loebenstein B.: An imbalance between pro-and anti-inflammatory cytokines, a characteristic feature of old age. Cytokine, 2000, 12: 1160-1161
131. Sayre L.M., Smith M.A., Perry G.: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem., 2001; 8: 721-738
132. Selkoe D.J.: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001; 81: 741-766
133. Selkoe D.J.: Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001; 98: 11039-11041
134. Selkoe D.J.: Alzheimer's disease is a synaptic failure. Science, 2002; 298: 789-791
135. Selkoe D.J., Schenk D.: Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol., 2003; 43: 545-584
136. Seltzer B.: Donepezil: an update. Expert Opin. Pharmacother., 2007; 8: 1011-1023
137. Senior K.: Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol., 2002; 1: 3
138. Serpell L.C.: Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta, 2000; 1502: 16-30
139. Shaftel S.S., Kyrkanides S., Olschowka J.A., Miller J.N., Johnson R.E., O'Banion M.K.: Sustained hippocampal IL-1b overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest., 2007; 117:1595-1604
140. Shimazaki M., Nakano H., Kobayashi K.: Correlation between tau phosphorylation sites and tangle morphology in Alzheimer disease. Psychogeriatrics, 2005; 5: 22-35
141. Siemers E., Skinner M., Dean R.A., Gonzales C., Satterwhite J., Farlow M., Ness D., May P.C.: Safety, tolerability, and changes in amyloid b concentrations after administration of a g-secretase inhibitor in volunteers. Clin. Neuropharmacol., 2005; 28: 126-132
142. Sisodia S.S., Kim S.H., Thinakaran G.: Function and dysfunction of the presenilins. Am. J. Hum. Genet., 1999; 65: 7-12
143. Small G.W., Kaufer D., Mendiondo M.S., Quarg P., Spiegel R.: Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int. J. Clin. Pract., 2005; 59: 473-477
144. Smith C., Graham D.I., Murray L.S., Nicoll J.A.: Tau immunochemistry in acute brain injury. Neuropathol. Appl. Neurobiol., 2003; 29: 496-502
145. Smith M.A., Joseph J.A., Perry G.: Arson. Tracking the culprit in Alzheimer's disease. Ann. NY Acad. Sci., 2000; 924: 35-38
146. Solomon B.: Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs, 2007; 16: 819-828
147. Soto C.: Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci., 2003; 4: 49-60
148. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., Frangione B.: β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med., 1998; 4: 822-826
149. Speciale L., Calabrese E., Saresella M., Tinelli C., Mariani C., Sanvito L., Longhi R., Ferrante P.: Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol. Aging, 2007; 28: 1163-1169
150. Srebro Z., Wili.ski B., Sura P.: Stres oksydacyjny w chorobie Alzheimera. Folia Med. Cracov., 2000; 41: 165-170
151. Stok.osowa S.: Hodowla komorek i tkanek. Wydawnictwo Naukowe PWN, 2004
152. Strle K., Zhou J.H., Shen W.H., Broussard S.R., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W.: Interleukin-10 in the brain. Crit. Rev. Immunol., 2001; 21: 427-449
153. Sugita-Konishi Y., Pestka J.J.: Differential upregulation of TNF-a, IL-6, and IL-8 production by deoxynivalenol (vomitoxin) and other 8-ketotrichothecenes in a human macrophage model. J. Toxicol. Environ. Health A, 2001; 64: 619-636
154. Suh Y.H., Checler F.: Amyloid precursor protein, presenilins, and asynuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev., 2002; 54: 469-525
155. Sylwanowicz W.: May atlas anatomiczny. PZWL, 1969
156. Szczepanik A.M., Funes S., Petko W., Ringheim G.E.: IL-4, IL-10 and IL-13 modulate A b(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol., 2001; 113: 49-62
157. Szczyrbowska M., Leszek J.: Wybrane zagadnienia immunologiczne u pacjentow w podesz.ym wieku. W: Choroby Ot.pienne. Teoria i praktyka. Wyd. Continuo, 2003; 243-257
158. Thomas R.S., Liddell J.E., Murphy L.S., Pache D.M., Kidd E.J.: An antibody to the β-secretase cleavage site on amyloid-b-protein precursor inhibits amyloid-b production. J. Alzheimers Dis., 2006; 10: 379-390
159. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., Tada K.: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer, 1980; 26: 171-176
160. Verwer R.W., Dubelaar E.J., Hermens W.T., Swaab D.F.: Tissue cultures from adult human postmortem subcortical brain areas. J. Cell. Mol. Med., 2002; 6: 429-432
161. Vetulani J.: Perspektywy terapii choroby Alzheimera. Psychogeriatria Pol., 2004; 1: 253-278
162. Wallin A.K., Andreasen N., Eriksson S., Batsman S., Nasman B., Ekdahl A., Kilander L., Grut M., Ryden M., Wallin A., Jonsson M., Olofsson H., Londos E., Wattmo C., Jonhagen M., Minthon L., Swedish Alzheimer Treatment Study Group: Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord., 2007; 23: 150-160
163. Walter J., Kaether C., Steiner H., Haass C.: The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol., 2001; 11: 585-590
164. Weber M.S., Prod'homme T., Steinman L., Zamvil S.S.: Drug insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol., 2005; 1: 106-112
165. Weiner H.L., Frenkel D.: Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol., 2006; 6: 404-416
166. Weksler M.E., Gouras G., Relkin N.R., Szabo P.: The immune system, amyloid-b peptide, and Alzheimer's disease. Immunol. Rev., 2005; 205: 244-256
167. Williams D.R.: Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Int. Med. J., 2006; 36: 652-660
168. Woodhouse A., Dickson T.C., Vickers J.C.: Vaccination strategies for Alzheimer's disease: A new hope? Drugs Aging, 2007; 24: 107-119
169. Wu J., Parungo C., Wu G., Kang P.M., Laham R.J., Sellke F.W., Simons M., Li J.: PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2. Circulation, 2004; 109: 1660-1667
170. Wyska E., Rosiak M.: Zastosowanie łańcuchowej reakcji polimerazy w czasie rzeczywistym (real-time PCR) w badaniach farmakokinetycznych. Post. Hig. Med. Dos̈w., 2006; 60: 660-666
171. Yanagisawa K.: Cholesterol and pathological processes in Alzheimer's disease. J. Neurosci. Res., 2002; 70: 361-366
172. Yeon S.W., Jeon Y.J., Hwang E.M., Kim T.Y.: Effects of peptides derived from BACE1 catalytic domain on APP processing. Peptides, 2007; 28: 838-844
173. Yuyama K., Yamamoto N., Yanagisawa K.: Chloroquine-induced endocytic pathway abnormalities: Cellular model of GM1 gangliosideinduced Ab fibrillogenesis in Alzheimer's disease. FEBS Lett., 2006; 580: 6972-6976
174. Žerovnik E.: Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur. J. Biochem., 2002; 269: 3362-3371